Joe Budman

Joe Budman currently serves as Vice President at Vicinitas Therapeutics since August 2022. Previously, Joe accumulated extensive experience at Theravance Biopharma US, Inc. from 2006 to February 2022, holding roles including Senior Director, Biology and Pharmacology, where leadership of a pan-JAK inhibitor project for ocular anti-inflammatory activity was achieved. Other notable roles included Director and Associate Director in Biology and Pharmacology, where Joe played a critical role in the discovery and clinical development of TD-6450 for HCV, as well as significant contributions to the discovery of TD-0212 as a bifunctional small molecule. Joe's academic journey includes earning a PhD in Biochemistry from Stanford University and a BS in Biology from the Massachusetts Institute of Technology, with early research experience at prestigious institutions including Stanford, Harvard, and MIT.